About this trial
The goal of this observational study is to learn about maternal psychiatric course and infant development in pregnant individuals with severe mental illness, comparing those treated with antipsychotics to those treated with other medications or without medication. The main questions it aims to answer are:
1. Is risk of psychiatric relapse different among individuals who take antipsychotic medication, other medication, or no medication? 2. Are pregnancy and neonatal health outcomes different among individuals who take antipsychotic medication, other medication, or no medication? 3. Do infant behavior and neurodevelopment differ among babies who were exposed to antipsychotic medication, other medication, or no medication in utero? Participants will
* complete a psychiatric interview and questionnaires while pregnant; * donate blood from the mother and from the umbilical cord at delivery * have their babies participate in infant behavior evaluations and an EEG procedure.
Researchers will compare these outcomes among individuals who were treated either with antipsychotic medication, with psychotropic medications of other classes, and with no medication, to see if psychiatric benefits for the mother and health outcomes for mother and child differ among these three types of treatment.
Eligibility criteria
Qualifiers
Pregnant
Psychotic disorder (affective and nonaffective)
Bipolar disorder
History of psychiatric hospitalization, regardless of diagnosis
Disqualifiers
Active substance use disorder in pregnancy
Insufficiently high-functioning to provide full informed consent and/or participate in study procedures
Trial design
Treatments tested in this trial
- Antipsychotics
- Non-antipsychotic medication
- No Medication
Treatment groups
Sponsors and collaborators
Icahn School of Medicine at Mount Sinai
Lead sponsor
Erasmus Medical Center
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator